- Report
- March 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- August 2025
- 189 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- February 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 375 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- September 2025
- 194 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- November 2024
- 90 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 190 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- March 2025
- 325 Pages
Global
From €4323EUR$4,950USD£3,755GBP
- Report
- December 2024
- 368 Pages
Global
From €4323EUR$4,950USD£3,755GBP
From €4323EUR$4,950USD£3,755GBP
- Report
- August 2025
- 140 Pages
Global
From €2619EUR$2,999USD£2,275GBP
- Report
- May 2025
- 148 Pages
Global
From €2619EUR$2,999USD£2,275GBP
- Report
- December 2024
- 100 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- April 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- August 2025
- 185 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more